ALB and hepatocellular carcinoma: Other than the pre-treatment serum ALB–BIL grade, a high on-treatment serum ALB–BIL grade was shown in a study conducted by Wang et al. [101] to independently predict worse OS in HCC patients receiving molecular targeted therapy with sorafenib followed by regorafenib.